Role for risk-scoring tools in identifying resistant pathogens in pneumonia: reassessing the value of healthcare-associated pneumonia as a concept

Current Opinion in Pulmonary Medicine
Andrew F Shorr, Marya D Zilberberg

Abstract

Resistant organisms remain a concern in patients presenting to hospital with pneumonia. Although in this setting the prevalence of various organisms such as methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa varies across the globe, patients infected with these pathogens are at increased risk for receiving an initially inappropriate antibiotic regimen - a major driver of mortality in all forms of pneumonia. The concept of healthcare-associated pneumonia (HCAP) was created to help clinicians identify persons at risk for infection with resistant pathogens, despite the onset of their infections occurring outside the hospital. However, it appears that HCAP, as currently defined, lacks adequate sensitivity and specificity for this purpose. Investigators have created various risk-scoring tools to stratify patients as to the likelihood that their infection is caused by a pathogen such as methicillin-resistant S. aureus or P. aeruginosa. These scores provide more precision at correctly segregating patients on the basis of the eventual recovery of resistant bacteria than does the HCAP syndrome. Most of these risk scores are easy to calculate and apply, and several have been externally validated. Physicians should con...Continue Reading

References

Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Aug 8, 2007·Antimicrobial Agents and Chemotherapy·Scott T MicekMarin H Kollef
Jun 22, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersAdam T Hill
Nov 24, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrew F ShorrMarin H Kollef
Nov 24, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stefano AlibertiFrancesco Blasi
Apr 5, 2013·Clinical Microbiology Reviews·Vered SchechnerMitchell J Schwaber
Jun 1, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rita L FinleyEdward Topp
Jul 17, 2013·American Journal of Respiratory and Critical Care Medicine·Yuichiro ShindoYoshinori Hasegawa
Sep 4, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Takaya MaruyamaMichael S Niederman
Oct 8, 2013·Critical Care Clinics·Henry Fraimow, Raquel Nahra
Nov 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James D ChalmersSantiago Ewig
Apr 29, 2014·Expert Opinion on Pharmacotherapy·Ilias Karaiskos, Helen Giamarellou
Sep 10, 2014·Annals of the New York Academy of Sciences·Elizabeth TemkinYehuda Carmeli
Nov 22, 2014·Critical Care : the Official Journal of the Critical Care Forum·Marya D ZilberbergMarin H Kollef

❮ Previous
Next ❯

Citations

Mar 19, 2015·Current Opinion in Pulmonary Medicine·Alimuddin Zumla, Michael S Niederman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.